France Adds Rubraca for Relapsed Platinum-sensitive Ovarian Cancer to Reimbursed Treatments

France Adds Rubraca for Relapsed Platinum-sensitive Ovarian Cancer to Reimbursed Treatments
Rubraca (rucaparib) is now available in France and eligible for reimbursement when used as a maintenance therapy by women with relapsed ovarian cancer who responded to platinum-based chemotherapy, regardless of their BRCA status, its developer, Clovis Oncology, announced. “Rubraca is effective across a broad population of women with relapsed ovarian cancer and is an important step in the ovarian cancer treatment pathway for eligible patients,” Patrick J. Mahaffy, the company's president and chief executive officer, said in a press release. Its reimbursement under the French public health system, together with availability, make it "a new treatment for patients with platinum-sensitive relapsed ovarian cancer,” added Anne Floquet, president of the SFOG, the French Society for Gyneco-Oncology. The oral treatment is a PARP inhibitor that works by blocking the activity of PARP enzymes that are responsible for repairing DNA in cells. By blocking the activity of these enzymes, Rubraca prevents cancer cells from repairing their DNA, ultimately destroying them. PARP inhibitors are particularly effe
Subscribe or to access all post and page content.